TY - JOUR
T1 - Potential clinical implications of mir-1 and mir-21 in heart disease and cardioprotection
AU - Kura, Branislav
AU - Kalocayova, Barbora
AU - Devaux, Yvan
AU - Bartekova, Monika
N1 - Funding Information:
Acknowledgments: This article is based upon work from EU‐CardioRNA COST Action (www.cardiorna.eu) supported by COST (European Cooperation in Science and Technology).
Funding Information:
The support for the infrastructure for this project was provided by grants from the Scientific Grant Agency of the Ministry of Education, Science, Research, and Sport of the Slovak Republic and the Slovak Academy of Sciences VEGA 2/0061/16 and VEGA 2/0104/20, and a grant from the Slovak Research and Development Agency APVV-15-0376. Y.D. was funded by the National Research Fund (grants #C14/BM/8225223 and #C17/BM/11613033), the Ministry of Higher Education and Research, and the Society for Research on Cardiovascular Diseases of Luxembourg. Acknowledgments: This article is based upon work from EU-CardioRNA COST Action CA17129 (www.cardiorna.eu) supported by COST (European Cooperation in Science and Technology).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - The interest in non-coding RNAs, which started more than a decade ago, has still not weakened. A wealth of experimental and clinical studies has suggested the potential of non-coding RNAs, especially the short-sized microRNAs (miRs), to be used as the new generation of therapeutic targets and biomarkers of cardiovascular disease, an ever-growing public health issue in the modern world. Among the hundreds of miRs characterized so far, microRNA-1 (miR-1) and microRNA-21 (miR-21) have received some attention and have been associated with cardiac injury and cardioprotection. In this review article, we summarize the current knowledge of the function of these two miRs in the heart, their association with cardiac injury, and their potential cardioprotective roles and biomarker value. While this field has already been extensively studied, much remains to be done before research findings can be translated into clinical application for patient’s benefit.
AB - The interest in non-coding RNAs, which started more than a decade ago, has still not weakened. A wealth of experimental and clinical studies has suggested the potential of non-coding RNAs, especially the short-sized microRNAs (miRs), to be used as the new generation of therapeutic targets and biomarkers of cardiovascular disease, an ever-growing public health issue in the modern world. Among the hundreds of miRs characterized so far, microRNA-1 (miR-1) and microRNA-21 (miR-21) have received some attention and have been associated with cardiac injury and cardioprotection. In this review article, we summarize the current knowledge of the function of these two miRs in the heart, their association with cardiac injury, and their potential cardioprotective roles and biomarker value. While this field has already been extensively studied, much remains to be done before research findings can be translated into clinical application for patient’s benefit.
KW - Biomarkers
KW - Cardioprotection
KW - Cardiovascular diseases
KW - MicroRNA-1 (miR-1)
KW - MicroRNA-21 (miR-21)
UR - http://www.scopus.com/inward/record.url?scp=85078311538&partnerID=8YFLogxK
U2 - 10.3390/ijms21030700
DO - 10.3390/ijms21030700
M3 - Review article
C2 - 31973111
AN - SCOPUS:85078311538
SN - 1661-6596
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 3
M1 - 700
ER -